Non-small-cell lung cancer: how to manage BRAF-mutated disease

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• BRAF mutations occur in 3-5% of non-small-cell lung cancer (NSCLC), primarily in adenocarcinoma.
• BRAF mutations are classified into three classes (V600 and non-V600), influencing therapeutic strategies.
• Limited evidence exists for treating this rare molecular subset of NSCLC.

Purpose of the Study:

• To provide a comprehensive update on therapeutic options for NSCLC patients with BRAF mutations.
• To guide physicians in selecting treatment strategies based on BRAF mutation status.
• To review the efficacy of targeted therapies and immunotherapy in BRAF-mutant NSCLC.

Main Methods:

• Review of single-arm phase II studies and retrospective analyses in advanced NSCLC.
• Inclusion of case reports and smaller experiences for specific BRAF alterations.
• Examination of retrospective data on immune-checkpoint inhibitors and immunotherapy consolidation post-chemoradiation.

Main Results:

• Efficacy data for BRAF and MEK inhibitors in both V600 and non-V600 mutations were collected.
• Retrospective evidence on immune-checkpoint inhibitors was reviewed; data on chemo-immunotherapy are lacking.
• Limited retrospective data on immunotherapy consolidation for unresectable stage III NSCLC were included.

Conclusions:

• Treatment strategies for BRAF-mutant NSCLC require careful consideration due to limited evidence.
• Targeted therapies (BRAF/MEK inhibitors) and immunotherapy show potential, with ongoing trials exploring new settings.
• Further research and clinical trials are crucial to optimize treatment for this specific NSCLC subgroup.